NeoGenomics: Chris Smith, Tony Zook

NeoGenomics CEO Chris Smith will retire from his role and his position as a board member effective April 1, 2025, at which time Tony Zook, an independent board member since 2023, will assume the role of CEO. Zook is a partner with Lucius Partners, a specialized healthcare consultancy providing financial, strategic, product development, and operational insights to emerging biopharmaceutical and medical device companies. Prior to his consulting work and role as CEO of Innocoll Pharmaceuticals, Zook was executive VP of global commercial operations at AstraZeneca. He was also president of MedImmune, AstraZeneca's wholly owned global biologics division, and chaired the firm's commercial investment board.

Smith will remain with the company as an advisor throughout the transition to ensure knowledge transfer and continuity.